Medical News

RSS

Revenue Cycle named official billing/coding consultant to ACRO

Revenue Cycle Inc. has again been named the official billing/coding consultant to the American College of Radiation Oncology (ACRO), according to Ron DiGiaimo, CEO of Revenue Cycle Inc.

12 Dec 2011

Neutra begins to test new proprietary nutrient formulas

Neutra Corp., an emerging provider of nutraceutical products and supplements, announced today that it has begun testing new proprietary nutrient formulas after receiving ingredient samples from potential suppliers.

12 Dec 2011

ETView files VIVASIGHT DL 510(k) Pre-Marketing Notification Application with FDA

ETView (TASE: ETVW) today announced that the company has successfully completed filing of a Pre-Marketing Notification Application (510(k)) with the US Food and Drug Administration.

12 Dec 2011

Reata, Abbott partner to develop and commercialize AIMs for chronic diseases

Abbott and Reata Pharmaceuticals today announced that they have entered into a worldwide collaboration to jointly develop and commercialize Reata's portfolio of second-generation oral antioxidant inflammation modulators.

12 Dec 2011

Technique expands scarce resources used for cord blood transplant procedure

A new method to boost the number of immune cells in umbilical cord blood prior to cord blood transplants for cancer patients appears to lead to a quicker rebuilding of a new immune system in the patient's body than with a conventional cord blood transplant procedure, according to new research from the Perelman School of Medicine at the University of Pennsylvania that will be presented today at the 53rd American Society of Hematology Annual Meeting.

12 Dec 2011

Treatment with leukemia patients' own cells may prevent infections after chemotherapy

A new treatment using leukemia patients' own infection-fighting cells appears to protect them from infections and cancer recurrence following treatment with fludarabine-based chemotherapy, according to new research from the Perelman School of Medicine at the University of Pennsylvania.

12 Dec 2011

Celgene announces interim results of REVLIMID study on CLL

Celgene International Sàrl, a subsidiary of Celgene Corporation, announced interim results of CLL-009, a study evaluating three starting doses of REVLIMID (lenalidomide), followed by step-wise dose escalation as tolerated in patients with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy.

12 Dec 2011

Scientists identify importance of novel protein-regulating mechanism

For years, science has generally considered the phosphorylation of proteins -- the insertion of a phosphorous group into a protein that turns it on or off -- as perhaps the factor regulating a range of cellular processes from cell metabolism to programmed cell death. Now, scientists from the Florida campus of The Scripps Research Institute have identified the importance of a novel protein-regulating mechanism -- called sulfenylation -- that is similar to phosphorylation and may, in fact, open up opportunities to develop new types of drugs for diseases such as cancer.

12 Dec 2011

National Autism Center releases new ASD manual for parents

Parents and caregivers everywhere are eager for credible, research-based information on the most effective treatments for Autism Spectrum Disorders.

12 Dec 2011

Rainbow Biosciences signs letter of intent to form new joint venture with n3D

Rainbow Biosciences, a division of Rainbow Coral Corp. announced today that it signed a letter of intent to acquire or form a new joint venture with cutting-edge biotech firm n3D Biosciences, Inc.

12 Dec 2011

Research assesses safety and efficacy of pre-operative transfusions, hydroxyurea therapy for SCD

Research assessing the safety and efficacy of hydroxyurea therapy in pediatric patients with sickle cell disease (SCD) and the use of pre-operative transfusions for patients with SCD who undergo low- and moderate-risk elective surgery will be presented today at the 53rd Annual Meeting of the American Society of Hematology.

12 Dec 2011

Research examines novel treatment techniques for hemophilia B, VTE

Bleeding and clotting disorders affect a large number of patients annually and, while accurate diagnosis is important, timely and effective treatment for these disorders is key, as they have the potential to quickly become life-threatening. Research examining novel treatment techniques for bleeding and clotting disorders will be presented today at the 53rd Annual Meeting of the American Society of Hematology.

12 Dec 2011

MyHeartMap Challenge to create nation's first crowd-sourced AED registry

A group of Penn Medicine researchers is set to save lives with cell phone cameras -- and they're challenging the public to help. The MyHeartMap Challenge, a month-long contest slated to take place beginning in mid January, will send thousands of Philadelphians to the streets and to social media sites to locate as many automated external defibrillators (AEDs) as they can.

12 Dec 2011

Onconova announces data from five rigosertib clinical trials on MDS

Onconova Therapeutics announces three presentations relating to clinical trials of its Phase III-stage anticancer agent, rigosertib sodium (Estybon or ON 01910.Na), at the 53rd American Society of Hematology (ASH) Annual Meeting in San Diego, CA, December 10-13, 2011.

12 Dec 2011

ICON agrees to acquire BeijingWits

ICON plc, a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today announced that it has agreed, subject to closing conditions, to acquire BeijingWits Medical Consulting Ltd., a leading CRO in China.

12 Dec 2011

Re-treatment with rituximab may benefit patients with LTB follicular lymphoma

Asymptomatic patients diagnosed with nonbulky follicular lymphoma, a slow-growing type of non-Hodgkin lymphoma, have traditionally been watched for signs or symptoms of disease progression and then treated with a combination of rituximab and chemotherapy or rituximab alone for select cases. Recent trials have suggested a role for treatment of asymptomatic patients with single-agent rituximab followed by additional periodic dosing, called "maintenance therapy."

12 Dec 2011

Chemotherapy can cause cognitive problems in breast cancer survivors

A new analysis has found that breast cancer survivors may experience problems with certain mental abilities several years after treatment, regardless of whether they were treated with chemotherapy plus radiation or radiation only.

12 Dec 2011

QSI enters agreement to acquire ViaTrack

Quality Systems, Inc., a leading provider of healthcare information systems and connectivity solutions, today announced that it has entered into an agreement to acquire ViaTrack Systems, a developer and provider of information technologies that enhance electronic data interchange (EDI) offerings.

12 Dec 2011

PCI-32765 is highly active and well tolerated in patients with CLL

An interim analysis of a phase Ib/II clinical trial indicates that a novel experimental agent for chronic lymphocytic leukemia (CLL) is highly active and well tolerated in patients who have relapsed and are resistant to other therapy.

12 Dec 2011

Onyx announces data from three carfilzomib studies on RRMM

Onyx Pharmaceuticals, Inc. today announced summaries of three poster presentations of single-agent carfilzomib, a next generation proteasome inhibitor, in patients with relapsed and/or refractory multiple myeloma at the 53rd American Society of Hematology (ASH) Annual Meeting in San Diego, CA.

12 Dec 2011